SCM
KZIA

Stonepine Capital Management’s Kazia Therapeutics KZIA Stock Holding History

Stonepine Capital Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.57M Sell
345,179
-115,180
-25% -$802K 1.03% 15
2025
Q4 		$3.17M Buy
+460,359
New +$3.92M 2.32% 10

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Stonepine Capital Management's KZIA Position: Q1 2026 in Review

Stonepine Capital Management reduced its Kazia Therapeutics (KZIA) stake by 25% in Q1 2026, selling an estimated $802K and leaving 345,179 shares worth $2.57M. The position accounts for 1.03% of the portfolio, ranked #15.

Stonepine Capital Management first reported a position in KZIA in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.17M in Q4 2025. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • Stonepine Capital Management held 345,179 shares of Kazia Therapeutics worth $2.57M as of Q1 2026.
  • Stonepine Capital Management sold 115,180 Kazia Therapeutics shares in Q1 2026, an estimated $802K.
  • Kazia Therapeutics made up 1.03% of Stonepine Capital Management's portfolio in Q1 2026, its #15 holding.
  • Stonepine Capital Management first reported a position in Kazia Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Stonepine Capital Management's Kazia Therapeutics position peaked at $3.17M in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.